

Rheumatology Grand Rounds

CME Credit provided by The University of Arizona College of Medicine – Tucson

Friday, March 13th, 2026

Joshua N, Farr, Ph.D.

Associate Professor

Ethel McChesney Chair for Osteoporosis Research

University of Arizona, Department of Medicine

Division of Rheumatology

The University of Arizona Arthritis Center

“Future Directions in Osteoporosis Therapy: Integrating Osteoanabolic Agents and Senescence-Targeted Strategies”

Rheumatology Grand Rounds: 9:00 – 10:00 AM

ZOOM Videoconference

Join from PC, Mac, Linux, iOS or Android: <https://arizona.zoom.us/j/86483330475>

Learning Objectives: Participants should be able to:

1. Describe the mechanisms and clinical evidence supporting osteoanabolic therapies for osteoporosis, including romosozumab and other anabolic agents.
2. Explain how skeletal aging and cellular senescence influence bone remodeling and therapeutic response.
3. Evaluate emerging strategies that integrate osteoanabolic therapies with senescence-targeted approaches to improve durability of osteoporosis treatment.

Target Audience: Physicians and other healthcare providers

Methodology: Grand Rounds Lecture

Accreditation Statement:

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Relevant Financial Relationships Statement(s):

University of Arizona Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Ernest Vina, MD, MS	Activity Director	Nothing to disclose – 10/17/2025
Joshua N. Farr, PhD	Faculty	Nothing to disclose – 1/16/2026

If you have any questions, please contact the Division of Rheumatology at 520-626-4111.

